These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17242769)

  • 61. Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies.
    Lee HJ; Sinha AA
    Autoimmunity; 2006 Sep; 39(6):433-44. PubMed ID: 17060022
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Beneficial effect of hydroxychloroquine on cutaneous lupus erythematosus in a Japanese girl.
    Yamamoto T; Hiraiwa T
    J Dermatol; 2014 Apr; 41(4):357-9. PubMed ID: 24617496
    [No Abstract]   [Full Text] [Related]  

  • 63. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus.
    Gammon B; Hansen C; Costner MI
    J Am Acad Dermatol; 2011 Oct; 65(4):717-721.e2. PubMed ID: 21641078
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Management of cutaneous lupus erythematosus with Janus kinase inhibitor therapy: An evidence-based review.
    Abduelmula A; Sood S; Mufti A; Hinek A; Yeung J
    J Am Acad Dermatol; 2023 Jul; 89(1):130-131. PubMed ID: 36935014
    [No Abstract]   [Full Text] [Related]  

  • 65. [Family Juvenile Systemic Lupus: about two families].
    Krich S; Inani K; Meziane M; Souilmi FZ; Atmani S; Hida M; Harmouch T; Amarti A; Mernissi FZ
    Pan Afr Med J; 2015; 20():419. PubMed ID: 26301023
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pregnancy and contraception in systemic and cutaneous lupus erythematosus.
    Guettrot-Imbert G; Morel N; Le Guern V; Plu-Bureau G; Frances C; Costedoat-Chalumeau N
    Ann Dermatol Venereol; 2016 Oct; 143(10):590-600. PubMed ID: 27129743
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment of cutaneous lupus erythematosus.
    Rothe MJ; Kerdel FA
    Lupus; 1992 Dec; 1(6):351-6. PubMed ID: 1304402
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.
    Kishi C; Motegi SI; Yasuda M; Ishikawa O
    J Dermatol; 2018 Aug; 45(8):1020-1022. PubMed ID: 30133802
    [No Abstract]   [Full Text] [Related]  

  • 69. Bullous lupus: an unusual initial presentation of systemic lupus erythematosus in an adolescent girl.
    Tincopa M; Puttgen KB; Sule S; Cohen BA; Gerstenblith MR
    Pediatr Dermatol; 2010; 27(4):373-6. PubMed ID: 20653856
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus.
    Fruchter R; Kurtzman DJB; Patel M; Merola J; Franks AG; Vleugels RA; Femia AN
    JAMA Dermatol; 2017 Sep; 153(9):937-939. PubMed ID: 28636714
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Three lianas syrup in treating 302 cases of various types of lupus erythematosus].
    Qin WZ
    Zhong Xi Yi Jie He Za Zhi; 1988 Oct; 8(10):604-6, 582. PubMed ID: 3255541
    [No Abstract]   [Full Text] [Related]  

  • 72. Novel biological therapeutic approaches to cutaneous lupus erythematosus.
    Tayer-Shifman OE; Rosen CF; Wakani L; Touma Z
    Expert Opin Biol Ther; 2018 Oct; 18(10):1041-1047. PubMed ID: 30118337
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus.
    Kwatra SG
    J Am Acad Dermatol; 2015 Aug; 73(2):e79. PubMed ID: 26184008
    [No Abstract]   [Full Text] [Related]  

  • 74. Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus.
    Werth VP; Dutz JP; Sontheimer RD
    Curr Opin Rheumatol; 1997 Sep; 9(5):400-9. PubMed ID: 9309195
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pimecrolimus 1% cream for cutaneous lupus erythematosus.
    Kreuter A; Gambichler T; Breuckmann F; Pawlak FM; Stücker M; Bader A; Altmeyer P; Freitag M
    J Am Acad Dermatol; 2004 Sep; 51(3):407-10. PubMed ID: 15337984
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lupus.
    Walton BG;
    Prairie Rose; 2004 Nov-2005 Jan; 73(4):22-6. PubMed ID: 15586556
    [No Abstract]   [Full Text] [Related]  

  • 77. Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients.
    Sonigo G; Jachiet M; Bessis D; Cordel N; Faucon C; Petit A; Cordoliani F; Bagot M; Senet P; Barbaud A; Bouaziz JD; Francès C; Chasset F;
    J Am Acad Dermatol; 2022 Jul; 87(1):203-206. PubMed ID: 34333080
    [No Abstract]   [Full Text] [Related]  

  • 78. Rosacea-like cutaneous lupus erythematosus: an atypical presentation responding to antimalarials.
    Marzano AV; Lazzari R; Polloni I; Boneschi V; Crosti C
    Acta Derm Venereol; 2013 Jan; 93(1):106-7. PubMed ID: 23053047
    [No Abstract]   [Full Text] [Related]  

  • 79. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation.
    Tzellos TG; Kouvelas D
    Eur J Clin Pharmacol; 2008 Apr; 64(4):337-41. PubMed ID: 18157526
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Remission of incapacitating acute cutaneous lupus erythematosus in a patient with systemic lupus erythematosus by B cell-depletive therapy.
    Kok MR; Vos K; Bos JD; Tak PP
    J Clin Rheumatol; 2010 Oct; 16(7):345. PubMed ID: 20859218
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.